Urch Publishing | Publication

Therapeutic

Title

Cancer Market Trends 2006 - 2010

Sub title

Key market forecasts and growth opportunities

Author

S. Seget

Publication date

December 2006

ISBN

1905751028

Pages

111

Price

pdf £1050 | print £1095

Summary

The global cancer market has just seen a period of rapid growth. Between 2003 and 2005, global sales for cancer treating drugs increased by 40% and now account for more than eight percent of total global pharmaceutical sales. Although growth rates for this market will slow due to generic competition the market is predicted to expand to $85.3 billion by 2010 equivalent to CAGR of 11.1%

Cancer Market Trends, 2006-2010 - Key market forecasts and growth opportunities provides a superb trend analysis of the growing cancer market.

This comprehensive report delivers market forecasts and overviews to help inform you in your pharmaceutical business decision-making.

Key findings from the report include:

The worldwide incidence of new cancer patients is forecast to increase from 4.2 million cases in the major cancer markets in 2005 to 4.6 million in 2010.

The cancer having the greatest impact on the population in the leading pharmaceutical markets is cancer of the trachea, bronchus and lung.

Global cancer market growth of 16.5% in 2005 was primarily driven by growth of 41.2% in innovative sales.

The worldwide cancer market is dominated by the selected adjuncts drug class with a market share of 38.3%, followed chemotherapeutics, innovatives and then hormonals.

Five of the top 10 leading cancer products in 2005 were selected adjuncts (Eprex/ Procrit, Aranesp, Epogen, Neulasta and NeoRecormon/ Epogin), two were innovatives (Rituxan/ MabThera and Gleevec/ Glivec), two were chemotherapeutics (Taxotere and Eloxatin) and one was a hormonal (Lupron).

14 pharmaceutical companies were identified as having generated cancer sales in excess of US$1 billion in 2005.

This report provides key information needed in your business including:

Sales forecast for top ten companies providing cancer treatment medicines.

Analysis of leading cancer products likely to loose patent protection in the next ten years.

Sales forecasts to 2010 for the top ten cancer medicines and forecasts by drug class.

Overview of disease incidence, areas of growth and breakdown of disease burden and mortality.

Breakdown of the major market trends and business opportunities

Use This Report To:
1. Benchmark your company’s portfolio against market trends and forecasts to plan better for greater profitability.
2. Spot areas of pharmaceutical market growth and good opportunities for delivering successful sales growth
3. Support your internal planning processes by using an external perspective founded on detailed analysis and transparent market forecasts.

The 111 page publication contains 49 Figures and 43 Tables to help you make sense of the wealth of data. This report will be of particular use to those involved in:
- corporate planning,
- sales and marketing,
- portfolio management, and,
- market forecasting.

The report is divided into five key sections. Chapters 2-5 present historical trends for key disease markets, key drug classes, key products and key companies. The final report chapter outlines future cancer market trends and major growth opportunities. The data and analysis contained within the report are comprehensive, consistent and up-to-date and thus provide a single-point of reference for understanding cancer market trends.

TABLE OF CONTENTS

Summary
Introduction
Key disease markets
Key drug classes
Key products
Key companies
Key trends and opportunities

Chapter 1 Introduction
Global cancer market
Report overview

Methodology
Sources
Structure

Chapter 2 Key disease markets Key cancer markets

Disease burden
Cancer incidence
Cancer mortality

Cancer epidemiology

Prostate cancer
Breast cancer
Lung and bronchus cancer
Colorectal cancer
Uterine corpus/ endometrium (uterus) cancer
Urinary bladder cancer
Non-Hodgkin’s lymphoma
Melanoma
Kidney and renal pelvis cancer
Leukemia

Cancer treatment-related disorders

Nausea and vomiting
Hematological disorders
Other cancer treatment side effects

Chapter 3 Key drug classes Key drug classifications
Hormonals drug class

Leading hormonal drugs

Chemotherapeutics drug class
Leading chemotherapeutic drugs Innovatives drug class

Leading innovative drugs

Selected adjuncts drug class

Leading selected adjunct drugs

Chapter 4 Key products
Leading products
Top 10 leading cancer drugs

Rituxan/ MabThera (rituximab)
Eprex/ Procrit (epoetin alfa)
Aranesp (darbepoetin alfa)
Epogen (epoetin alfa)
Neulasta (pegfilgrastim)
Gleevec/ Glivec (imatinib mesylate)
Taxotere (docetaxel)
Lupron (leuprolide acetate)
Eloxatin (oxaliplatin)
NeoRecormon/ Epogin (epoetin beta)

Chapter 5 Key companies
Major cancer players
Leading companies

Amgen
Novartis
Roche
Sanofi-Aventis
Genentech
AstraZeneca
Johnson & Johnson
Pfizer
GlaxoSmithKline
Eli Lilly

Chapter 6 Key trends and opportunities
Key disease market forecasts

Global markets
Cancer sites

Key drug class forecasts

Hormonals
Chemotherapeutics
Innovatives
Selected adjuncts

Key product forecasts

Key company forecasts

Amgen
Novartis
Roche
Sanofi-Aventis
Genentech
AstraZeneca
Johnson & Johnson
Pfizer
GlaxoSmithKline
Eli Lilly

Appendix Proprietary data sources

Product Trends Database
R&D Trends Database
Company Trends Database
Market Trends Database

Top 46 cancer products
Top 14 pharmaceutical companies by cancer sales

Figures
Figure 1: Global cancer market, 2003-2005
Figure 2: Report structure
Figure 3: Disease burden in seven major pharmaceutical markets, 2005
Figure 4: New cancer cases in the US, 2006
Figure 5: Cancer deaths in the US, 2006
Figure 6: Cancer epidemiology in seven major markets, 2005
Figure 7: Prostate cancer epidemiology in seven major markets, 2005
Figure 8: Breast cancer epidemiology in seven major markets, 2005
Figure 9: Lung and bronchus cancer epidemiology in seven major markets, 2005
Figure 10: Colorectal cancer epidemiology in seven major markets, 2005
Figure 11: Uterine corpus/ endometrium (uterus) cancer epidemiology in seven major markets, 2005
Figure 12: Urinary bladder cancer epidemiology in seven major markets, 2005
Figure 13: Non-Hodgkin’s lymphoma epidemiology in seven major markets, 2005
Figure 14: Melanoma epidemiology in seven major markets, 2005
Figure 15: Kidney and renal pelvis cancer epidemiology in seven major markets, 2005
Figure 16: Leukemia epidemiology in seven major markets, 2005
Figure 17: Global cancer market by drug class, 2005
Figure 18: Global cancer market by drug class, 2003-2005
Figure 19: Global cancer market trends by drug class, 2004-2005
Figure 20: Hormonals market, 2003-2005
Figure 21: Leading hormonal drugs by approval date, 1977-2005
Figure 22: Chemotherapeutics market, 2003-2005
Figure 23: Leading chemotherapeutic drugs by approval date, 1989-2005
Figure 24: Innovatives market, 2003-2005
Figure 25: Leading innovative drugs by approval date, 1983-2005
Figure 26: Selected adjuncts market, 2003-2005
Figure 27: Leading selected adjunct drugs by approval date, 1988-2005
Figure 28: Cancer blockbuster trends, 2004-2005
Figure 29: Top 10 cancer products by global sales, 2005
Figure 30: Top 10 companies by global cancer sales, 2005
Figure 31: Top 10 companies by global cancer market share, 2005
Figure 32: Top 10 companies by global cancer sales, 2004-2005
Figure 33: Cancer incidence forecasts by geographic market, 2005-2010
Figure 34: Cancer incidence forecasts by disease market, 2005-2010
Figure 35: Global cancer market forecast, 2003-2010
Figure 36: Global cancer market forecasts by drug class, 2003-2010
Figure 37: Top 10 cancer drugs by forecast sales, 2010
Figure 38: Rituxan/ MabThera (rituximab) forecast sales, 2003-2010
Figure 39: Eprex/ Procrit (epoetin alfa) forecast sales, 2003-2010
Figure 40: Aranesp (darbepoetin alfa) forecast sales, 2003-2010
Figure 41: Epogen (epoetin alfa) forecast sales, 2003-2010
Figure 42: Neulasta (pegfilgrastim) forecast sales, 2003-2010
Figure 43: Gleevec/ Glivec (imatinib mesylate) forecast sales, 2003-2010
Figure 44: Taxotere (docetaxel) forecast sales, 2003-2010
Figure 45: Lupron (leuprolide acetate) forecast sales, 2003-2010
Figure 46: Eloxatin (oxaliplatin) forecast sales, 2003-2010
Figure 47: NeoRecormon/ Epogin (epoetin beta) forecast sales, 2003-2010
Figure 48: Forecast patent expiries by 2005 global sales, 2006-2015
Figure 49: Top ten companies by cancer sales trends, 2005-2010

Tables
Table 1: Global cancer market trends by drug class, 2003-2005
Table 2: Leading hormonal drugs, 2005
Table 3: Hormonals market trends, 2003-2005
Table 4: Leading chemotherapeutic drugs, 2005
Table 5: Chemotherapeutics market trends, 2003-2005
Table 6: Leading innovative drugs, 2005
Table 7: Innovatives market trends, 2003-2005
Table 8: Leading selected adjunct drugs, 2005
Table 9: Selected adjuncts market trends, 2003-2005
Table 10: Top 20 cancer products by global sales, 2003-2005
Table 11: Rituxan/ MabThera (rituximab) profile, 2005
Table 12: Eprex/ Procrit (epoetin alfa) profile, 2005
Table 13: Aranesp (darbepoetin) profile, 2005
Table 14: Epogen (epoetin alfa) profile, 2005
Table 15: Neulasta (pegfilgrastim) profile, 2005
Table 16: Gleevec/ Glivec (imatinib mesylate) profile, 2005
Table 17: Taxotere (docetaxel) profile, 2005
Table 18: Lupron (leuprolide) profile, 2005
Table 19: Eloxatin (oxaliplatin) profile, 2005
Table 20: NeoRecormon/ Epogin (epoetin beta) profile, 2005
Table 21: Top 10 companies by global cancer sales, 2003-2005
Table 22: Amgen profile, 2005
Table 23: Amgen cancer pipeline, 2005
Table 24: Novartis profile, 2005
Table 25: Novartis cancer pipeline, 2005
Table 26: Roche profile, 2005
Table 27: Roche cancer pipeline, 2005
Table 28: Sanofi-Aventis profile, 2005
Table 29: Sanofi-Aventis cancer pipeline, 2005
Table 30: Genentech profile, 2005
Table 31: Genentech cancer pipeline, 2005
Table 32: AstraZeneca profile, 2005
Table 33: AstraZeneca cancer pipeline, 2005
Table 34: Johnson & Johnson profile, 2005
Table 35: Johnson & Johnson cancer pipeline, 2005
Table 36: Pfizer profile, 2005
Table 37: Pfizer cancer pipeline, 2005
Table 38: GlaxoSmithKline profile, 2005
Table 39: GlaxoSmithKline cancer pipeline, 2005
Table 40: Eli Lilly profile, 2005
Table 41: Eli Lilly cancer pipeline, 2005
Table 42: Global cancer market forecasts by drug class, 2003-2010
Table 43: Top 10 cancer drugs forecasts, 2003-2010
Table 44: Top 10 companies by cancer sales forecasts, 2005-2010
Table 45: Top 46 cancer products by global pharmaceutical sales, 2003-2005
Table 46: Top 14 companies by global cancer sales, 2003-2005

Therapeutic

Steven Seget is Principal at Delphi Pharma, and provides independent strategic consulting services to the pharmaceutical and biotechnology industries.

Delphi Pharma provides strategic, financial and market–based solutions to clients, focusing primarily on the portfolio management and licensing functions.